2023 World Conference on Lung Cancer (Posters)-EP14.01. Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab.

EP14.01. Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab. - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the clinical significance of BAP1 expression in malignant mesothelioma (MPM) patients treated with a combination of ipilimumab (IPI) and nivolumab (NIVO) immunotherapy. MPM is a rare disease with limited treatment options, and the IPI/NIVO combination therapy has shown promising results. However, there is no defined predictive biomarker for immunotherapy in MPM, even though there have been advancements in molecular studies.<br /><br />The researchers retrospectively analyzed the clinical data of 27 MPM patients who were treated with IPI and NIVO between 2021 and 2023. The patients had unresectable or metastatic MPM and received the immunotherapy for up to 2 years. The histological subtypes of the patients varied, with 16 having epithelioid type, 7 biphasic type, and 4 sarcomatoid type.<br /><br />The overall response rate to the combination therapy was 32%, with 3 patients achieving complete response (CR) and 5 patients achieving partial response (PR). The median progression-free survival (PFS) was 4 months. The researchers evaluated the expression of programmed death-ligand 1 (PDL1) and the status of BAP1 in the patients. It was found that patients with loss of BAP1 signature had significantly longer PFS compared to those with intact or unknown BAP1 status.<br /><br />The results suggest that the IPI and NIVO combination therapy is a well-tolerated treatment option, especially for MPM patients with BAP1 signature loss. However, further data maturity is needed to confirm these findings. The study highlights the potential of BAP1 as a predictive biomarker for immunotherapy in MPM, providing insights for personalized treatment strategies in the future.<br /><br />Keywords: Malignant pleura mesothelioma, Ipilimumab, Nivolumab, BAP1.

Asset Subtitle

Sook-hee Hong

Meta Tag

Speaker Sook-hee Hong

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

Malignant pleura mesothelioma

Ipilimumab

Nivolumab

BAP1

Clinical significance

Immunotherapy

Predictive biomarker

Overall response rate

Progression-free survival

Personalized treatment strategies